Citigroup
BBLG

Citigroup’s Bone Biologics BBLG Stock Holding History

Citigroup’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-206
Closed -$575 – 6079
2025
Q3 		$575 Buy
+206
New +$522 ﹤0.01% 5694
2025
Q1 		– Sell
-825
Closed -$4.65K – 5588
2024
Q4 		$4.65K Buy
+825
New +$6.79K ﹤0.01% 5470

Other funds holding BBLG

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's BBLG Position: Q4 2025 in Review

Citigroup sold out of Bone Biologics (BBLG) in Q4 2025, closing a stake of 206 shares — an estimated $575 sold.

Citigroup first reported a position in BBLG in Q4 2024 and held it in 2 quarters. The position peaked at $4.65K in Q4 2024. 7 funds tracked by Wall St. Rank hold BBLG as of Q4 2025.

  • Citigroup reported no remaining Bone Biologics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 206 Bone Biologics shares in Q4 2025, an estimated $575.
  • Citigroup first reported a position in Bone Biologics in Q4 2024 and held it in 2 quarters.
  • Citigroup's Bone Biologics position peaked at $4.65K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held Bone Biologics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.